Google sis­ter Ver­i­ly sports an­oth­er im­pres­sive raise, haul­ing in $700M to sup­port its two big plat­forms

5 years ago
Financing

In his­toric vote, mR­NA vac­cines go 2 and 0 as FDA ex­perts unan­i­mous­ly back Mod­er­na's Covid-19 vac­cine

5 years ago
R&D
Coronavirus

Glax­o­SmithK­line, Vir look to suc­ceed where Lil­ly failed with NIH an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

5 years ago
R&D
Coronavirus

Af­ter los­ing race for first to mar­ket in lu­pus nephri­tis, Au­rinia taps Ot­su­ka for vo­closporin li­cens­ing pact abroad

5 years ago
Deals

'A prece­dent you might not want to set.' FDA-in­vit­ed ex­pert blasts Mod­er­na un­blind­ing plan as ad­comm gets un­der­way

5 years ago
Coronavirus

A boom­ing mar­ket pro­pels Chi­na CRO to a $100M raise. Is an IPO next?

5 years ago
Financing
China

News brief­ing: British psy­che­del­ic in­vest­ment firm launch­es; Irish cell ther­a­py com­pa­ny gains ex­clu­sive li­cense ...

5 years ago
News Briefing

Mi­nor­i­ty in­vestor Wa­ter­Mill suc­ceeds in ac­tivist at­tack of Zio­pharm, win­ning two board seats and re­moval of chair­man

5 years ago
Pharma

Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy ...

5 years ago
Deals

Glax­o­SmithK­line's Benlysta earns first FDA ap­proval for lu­pus nephri­tis as com­peti­tors wait in the wings

5 years ago
Pharma
FDA+

The biotech IPO train keeps chug­ging, as Virios prices $30M pub­lic de­but

5 years ago
Financing

Con­tin­u­ing rapid ex­pan­sion, Ther­mo Fish­er says it will add on plas­mid DNA man­u­fac­tur­ing site in Cal­i­for­nia

5 years ago
Outsourcing
Manufacturing

Covid-19 roundup: FDA gives OK to use ex­tra dos­es in Pfiz­er/BioN­Tech vac­cine vials; Sinophar­m's Pe­ru tri­al to re­sume

5 years ago
Coronavirus

Am­gen sends first KRAS drug to the FDA, ap­proval could fol­low swift­ly

5 years ago
FDA+

Ab­b­Vie's Covid-19 an­ti­body part­ner wraps $221M Hong Kong IPO

5 years ago
Financing
China

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

5 years ago
Deals

Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

5 years ago
Pharma
FDA+

EX­CLU­SIVE: As­traZeneca makes tough un­blind­ing call, grap­pling with a vac­cine roll­out that threat­ens to im­pair their ...

5 years ago
Coronavirus

Vi­vace Ther­a­peu­tics scores $30M Se­ries C to take on­col­o­gy can­di­date for 'Hip­po' path­way to hu­man tri­al next year

5 years ago
Financing

Sam­sung Bi­o­log­ics pro­motes new CEO from with­in to head next phase of rapid man­u­fac­tur­ing ex­pan­sion

5 years ago
People
Outsourcing

News brief­ing: Bob Cough­lin is jump­ing in­to re­al es­tate — in a big way; Keytru­da plus Lenvi­ma posts pos­i­tive PhI­II ...

5 years ago
News Briefing

BioAt­la heads for Nas­daq on Wednes­day fol­low­ing $189M IPO, go­ing pub­lic with its pH-de­tect­ing can­cer treat­ments

5 years ago
Financing

No­var­tis sets eyes on new­ly-ac­quired Alex­ion with break­through tag for rare dis­ease hope­ful ip­ta­co­pan

5 years ago
Pharma
FDA+

Af­ter leav­ing Wall Street to launch a gene ther­a­py up­start, Rachel McMinn nabs $115M to dri­ve her first can­di­date to ...

5 years ago
Financing
Cell/Gene Tx
First page Previous page 764765766767768769770 Next page Last page
A service from the Financial Times